What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run

3 hours ago 1

Jonathan Ponciano, The Motley Fool

Sun, January 11, 2026 astatine 3:12 PM CST 5 min read

The main ineligible serviceman of Disc Medicine sold 6,500 shares of the institution for $511,472 connected Jan. 2.
The merchantability represented 14.68% of Khara's nonstop holdings, arsenic reported astatine the time, reducing his nonstop ownership from 44,293 to 37,793 shares.
This was a derivative-linked transaction, involving the workout of vested options and contiguous merchantability of the underlying shares, with nary indirect entities oregon trusts involved.
These 10 stocks could mint the adjacent question of millionaires ›

On Jan. 2, Rahul Khara, the main ineligible serviceman of Disc Medicine (NASDAQ:IRON), exercised and instantly sold 6,500 shares successful a derivative transaction valued astatine astir $511,472, according to an SEC Form 4 filing.

Metric

Value

Shares sold (direct)	6,500
Transaction value	$511,471.8
Post-transaction shares (direct)	37,793
Post-transaction worth (direct ownership)	$2.99 million

Transaction worth based connected SEC Form 4 weighted mean acquisition price; post-transaction worth based connected the Jan. 2 marketplace close.

How important was this transaction comparative to Khara's anterior activity?
The 6,500-share workout and merchantability aligns with the caller median administrative merchantability size of 7,000 shares, representing 14.7% of nonstop holdings, which is accordant with the 13.28% median for the past year.
What does the derivative discourse bespeak astir insider intent?
This transaction was a structured, non-discretionary merchantability of shares acquired done enactment exercise, alternatively than an open-market discretionary sale.
How did this merchantability impact Khara's remaining capableness and ownership?
Direct holdings declined to 37,793 shares; Khara besides reported holding banal options underlying 22,270 shares.
What is the marketplace discourse for this transaction?
The transaction occurred astatine a weighted mean terms of $78.69 per share; implicit the trailing year, Disc Medicine shares delivered a 26.6% instrumentality arsenic of the transaction date.

Metric

Value

Price (as of Jan. 2)	$78.69
Market capitalization	$2.95 billion
Net income (TTM)	($181.11 million)
1-year terms change	26.6%

* 1-year terms alteration calculated utilizing Jan. 2, 2026 arsenic the notation date.

Disc Medicine, Inc. develops and advances clinical-stage therapeutic candidates targeting hematologic diseases, with a absorption connected reddish humor compartment biology, heme biosynthesis, and robust homeostasis.
The institution operates a biotechnology concern model, investing successful probe and improvement to bring caller therapies done objective trials toward regulatory support and aboriginal commercialization.
Primary customers see healthcare providers and institutions treating patients with superior hematologic disorders, peculiarly those with unmet aesculapian needs successful reddish humor compartment and robust regulation.